1[1]Koechli OR,Avner BP,Sevin BU,et al.Application of the adenosine triphosphate-cell viability assay in human breast cancer chemosensitivity testing:a report on the first results[J].J Surg Oncol,1993,54(2):119—25.
3[3]Xu JM,Song ST,Tang ZM,et al.Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro[J].Breast Cancer Res Treat,1999,53(1):77—85.
5Sun Z J, Yu T, Chen JS, et al. Effects of uhnastatin and cy- clophosphamide on the growth of xenograft breast cancer and ex- pression of CXC chemokine receptor 4 and matrix metallopro- teinase-9 in cancers [J]. J Int Med Res, 2010, 38 (3): 967-976.
6Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer [J]. Cancer Res, 2007, 67 (8): 3818-3826.
7Fite A, Goua M, Wahle KW, et al. Potentiation of the anti-tu- mour effect of docetaxel by conjugated linoleie acids (CLAs) in breast cancer cells in vitro [J]. Prostaglandins Leukot Essent Fatty Acids, 2007, 77(2): 87-96.
8Kobayashi H, Shinohara H, Takeuchi K, et al. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis [J]. Cancer Res, 1994, 54 (3): 844-849.
9Falandry C, Canney PA, Freyer G, et al. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer [Jl. Ann Oncol, 2009, 20 (4): 615- 620.
10Ghosh N, Chaki R, Mandal V, et al. COX-2 as a target for cancer chemotherapy [J]. Pharmacol Rep, 2010, 62 (2): 233-244.
